A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane in Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors VCN Biosciences
- 07 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
- 07 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2016.
- 07 Jul 2016 Status changed from recruiting to active, no longer recruiting.